You Searched For "Novartis" and got 20 results
Sort By:
Drug giant Novartis is going after a $5 billion eye-drug market
In data presented Friday at the American Academy of Opthamology annual conference, Novartis' drug b…
Lydia Ramsey
Aurobindo and Intas submit binding offers to buyout Teva UK
Teva is selling its assets after it acquired Allergan Plc's generics business for $40.5-billion in …
The CEO of Novartis wants to 'un-boss' the $230 billion pharma giant, and he's starting with letting employees wear jeans to work
"For many people, they love the idea of the culture change, everybody then wants to know why can't …
Lydia Ramsey
The top scientist at AveXis told us about this surprising reason that it got bought for $9 billion by Novartis, and it could shape the future of gene therapy
Knudten's background was in pharmaceuticals manufacturing, though not specifically in the type of g…
Emma Court
Elizabeth Warren and Bernie Sanders just slammed the Swiss drug giant Novartis over a new controversy swirling around the world's most expensive drug
In the pharmaceutical industry, where data is the basis for approvals of life-or-death drugs, data …
Emma Court
Pharma giant Novartis has been on a tear. CEO Vas Narasimhan told us how wearing jeans to work is helping transform the Swiss company.
So far it's working, though it'll ultimately be a five-year journey, Narasimhan told Business Insid…
Emma Court,Matt Turner
A small boutique landed a lucrative lead role on the $8.7 billion Novartis-AveXis deal
Gordon Dyal was a partner at Goldman Sachs for 16 years, rising to the role of co-chairman of the i…
Alex Morrell
Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky
Novartis' Sandoz plans to launch the higher-dose version of Symjepi, which is intended for those wh…
Emma Court
Novartis is betting that AI is the 'next great tool' for finding new, cutting-edge medicines. Here's how the $220 billion drug giant is using it
"Amazon knows just what ad to put at the bottom of the page when I order my squash racket. But the …
Emma Court,Matt Turner
A top executive at Swiss drug giant Novartis told us the inside story of the $2.1 million price tag for the most expensive drug in the world
Payers have also been very interested in agreements where a portion of the price tag is returned in…
Emma Court
Novartis is going after a $5 billion market with a new treatment for vision loss. That's a big threat to Regeneron
Age-related macular degeneration is a leading cause of vision loss in the US in people over 50, acc…
Lydia Ramsey
Swiss drug giant Novartis has done $60 billion in deals over the past 18 months. One sentence from its CEO reveals the core strategy.
Most biotech companies don't yet sell a product, so investors instead bet on factors like the promi…
Emma Court,Matt Turner
Philanthropy and CSR are fine, but Harvard senior fellow Mark Kramer sees CSV as the way forward for a growing and evolving India
CSV is a new approach of finding the synergy or overlap between a successful business and a success…
Prosecutors are now reportedly investigating Michael Cohen over the millions he accepted from companies like AT&T and Novartis
Failure to disclose those payments may have been in violation of federal disclosure laws, including…
Allan Smith
Pharma giants like Novartis, Pfizer, and Sanofi are getting serious about a cutting edge therapy that changes human genes
Recent M&A transactions show that big pharma is betting big on gene therapy. In April, Novartis…
Lydia Ramsey
'These are extraordinarily serious allegations': Pharma giant Novartis faces questions over payments to a Michael Cohen-linked organization
Novartis was contacted in November 2017 by lawyers from the Special Counsel's office regarding the …
Lydia Ramsey
A major data-manipulation scandal has rocked Novartis. Here's everything we learned from a new 59-page letter the Swiss drug giant sent to its regulators.
Featured Digital Health Articles: - Telehealth Industry: Benefits, Services & Examples - Valu…
Emma Court
Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases
Novartis isn't the only big pharma/biotech to be interested in gene and cell therapies. In January,…
Lydia Ramsey
'We're light years ahead of where we were': Novartis CEO Vas Narasimhan told us how the Swiss drug giant is using AI for everything from evaluating managers to predicting its financials
A long-running effort termed "Data 42" aims to mine Novartis research data for paths to new drugs. …
Emma Court,Matt Turner
DIGITAL HEALTH BRIEFING: Top announcements from HIMSS 2018 - Novartis looks into virtual drug trials - Value-based care could hurt small hospitals
THE MOVE TO VALUE-BASED CARE COULD LEAVE OUT SMALLER HOSPITALS: Smaller hospitals and independent …